Stay updated on Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial
Sign up to get notified when there's something new on the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page.

Latest updates to the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page
- Check4 days agoChange DetectedThe sponsor line 'Naurex, Inc, an affiliate of Allergan plc' was removed. The sections 'More Information' and 'Helpful Links Provided by' were also removed.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. No study data or user-facing content was changed.SummaryDifference0.0%

- Check69 days agoChange DetectedThe update shows a minor revision from v3.4.0 to v3.4.1 with no observable impact on study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedUI and metadata updates on the study page include a glossary display option and the addition of a 'Last Update Submitted that Met QC Criteria' field. These changes also remove the older 'No FEAR Act data' item and the prior revision (v3.3.4), replacing it with 'Revision: v3.4.0'.SummaryDifference0.1%

Stay in the know with updates to Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rapastinel Long-term Safety in Major Depressive Disorder Clinical Trial page.